Insiders' substantial selling of Chemed shares over the past year, especially in the last quarter, could be a red flag for investors. The absence of insider purchases during the same period heightens this concern. Despite high insider ownership, the history of share sales adds uncertainty.
Chemed's consistent ability to generate high returns on increased capital employed makes it a potential multi-bagger. Despite the stock being more 'expensive' than before, its strong fundamentals make it worthy of further research.
Despite Chemed's poor recent earnings, the high P/E ratio shows investors foresee future growth. They think chances of an earnings slump is low, supporting share price. This suggests strong future growth potential might be making investors pay a premium for the stock.
The market seems to have a higher opinion of Chemed as compared to five years ago, reflecting increased investor sentiment. Recent shareholder returns suggest positive sentiment around the company, possibly hinting at business momentum.
Chemed股票討論區
專欄US Top Gap Ups and Downs on 7/27: MU, ALGN, CMG, EBAY and More
Gap Ups
1. $艾利科技(ALGN.US)$ - up 11.5%
2. $德事隆(TXT.US)$ - up 5.2%
3. $意法半導體(STM.US)$ - up 4.1%
4. $泛林集團(LRCX.US)$ - up 3.9%
5. $RELX PLC(RELX.US)$ - up 3.1%
6. $皇家加勒比郵輪(RCL.US)$ - up 3.1%
7. $美光科技(MU.US)$ - up 3.1%
8. $西部數據(WDC.US)$ - up 2.9...
2023Q1營收增長5.6%,營業利潤下滑15%,淨利潤下滑15.7%,主要是毛利率下滑導致。
當前價格536.3,市盈率32.4,市盈率TTM微增到33.8,缺乏足夠的增長數據支持。
暫無評論